185 related articles for article (PubMed ID: 30151212)
1. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies.
Brown K; Mendell J; Ohwada S; Hsu C; He L; Warren V; Dishy V; Zahir H
Pharmacol Res Perspect; 2018 Oct; 6(5):e00418. PubMed ID: 30151212
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
Li Y; Toyama K; Nakatsu T; Ishizuka H; Wu H; Cao G; Yu J; Wang Y; Liu X; Guo B; Wu J; Yu P; Hong Z; Zhang J; Wu X
Adv Ther; 2023 Apr; 40(4):1628-1643. PubMed ID: 36790683
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
Jansen M; Warrington S; Dishy V; Ohwada S; Johnson L; Brown K; Ishizuka H
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):661-669. PubMed ID: 29663714
[TBL] [Abstract][Full Text] [Related]
4. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
Kato J; Baba M; Kuroha M; Kakehi Y; Murayama E; Wasaki Y; Ohwada S
Clin Ther; 2021 May; 43(5):822-835.e16. PubMed ID: 34059327
[TBL] [Abstract][Full Text] [Related]
7. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain.
Hutmacher MM; Frame B; Miller R; Truitt K; Merante D
J Clin Pharmacol; 2016 Jan; 56(1):67-77. PubMed ID: 26073181
[TBL] [Abstract][Full Text] [Related]
8. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial.
Kato J; Matsui N; Kakehi Y; Murayama E; Ohwada S
Medicine (Baltimore); 2020 Sep; 99(36):e21976. PubMed ID: 32899037
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study.
Tachibana M; Yamamura N; Atiee GJ; Hsu C; Warren V; He L; Dishy V; Zahir H
Br J Clin Pharmacol; 2018 Oct; 84(10):2317-2324. PubMed ID: 29920736
[TBL] [Abstract][Full Text] [Related]
11. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.
Baba M; Matsui N; Kuroha M; Wasaki Y; Ohwada S
J Diabetes Investig; 2019 Sep; 10(5):1299-1306. PubMed ID: 30672128
[TBL] [Abstract][Full Text] [Related]
12. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
van der Aar E; Desrivot J; Dupont S; Heckmann B; Fieuw A; Stutvoet S; Fagard L; Van de Wal K; Helmer E
J Clin Pharmacol; 2019 Oct; 59(10):1366-1378. PubMed ID: 31012984
[TBL] [Abstract][Full Text] [Related]
13. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects.
McColm J; Brittain C; Suriyapperuma S; Swanson S; Tauscher-Wisniewski S; Foster J; Soon D; Jackson K
Br J Clin Pharmacol; 2017 Aug; 83(8):1654-1667. PubMed ID: 28156011
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects.
Jansen M; Mendell J; Currie A; Dow J; He L; Merante D; Dishy V; Ishizuka H; Zahir H
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):597-612. PubMed ID: 29870596
[TBL] [Abstract][Full Text] [Related]
16. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
17. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.
Xiao F; Zhang F; Zhang LL; Wei W
Eur J Clin Pharmacol; 2018 Jan; 74(1):69-77. PubMed ID: 29051989
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
